The 340B program helps certain healthcare groups buy outpatient drugs at discounted prices. These groups are called covered entities and include hospitals and clinics serving people who need help. Discounts can be from 20% to 50%. This helps make medicines cheaper for patients who may not have insurance or have low income.
To join the program, covered entities must register with the Health Resources and Services Administration (HRSA). They must follow program rules. One important rule is to keep clear records that can be audited. These records must show every 340B drug bought and given to an eligible patient. This stops the discounted drugs from being used for people who do not qualify, which is called preventing “diversion.”
Proof of Compliance: Records prove that 340B drugs go only to patients who qualify. Covered entities must show the patient has a relationship with the entity, meaning the entity’s staff gave care.
Prevention of Diversion and Duplicate Discounts: Records help stop drugs from being given to the wrong patients or sold outside the program. They also stop duplicate discounts, where Medicaid rebates and 340B discounts happen on the same drug, which is not allowed.
Preparation for HRSA Audits: HRSA audits about 200 times a year. They check if entities follow rules and have good records. Bad records can lead to fines or being kicked out of the program.
Financial Protection: Good records reduce risks of paying back money or fines. In 2024, 18% of audits found issues needing repayments. Fines can go up to $6,000 for each mistake.
Complex Billing and Inventory Systems: Tracking drugs bought and given out in different places is hard. Hospitals must keep outpatient and inpatient drugs separate to avoid errors.
Contract Pharmacy Oversight: Using many pharmacies makes record keeping harder. If there are more than five contract pharmacies, HRSA watches closely. Detailed records from all locations are needed.
Data Integration and Documentation Gaps: Electronic health records, pharmacy software, and finance systems often don’t work well together. This causes missing or incorrect information, making audits harder.
Regulatory Complexity and Ongoing Changes: HRSA changes rules regularly. Staff must keep learning and adjust processes to stay compliant.
Resource Constraints: Keeping up with 340B rules needs time and skill. Smaller practices may struggle with policies, audits, and managing inventory.
If entities do not keep proper records or bill correctly, they lose savings from discounted drugs. Errors can cause fines and require paying back manufacturers. In 2024, enforcement actions included ending some contract pharmacies and fines near $6,000 per mistake.
Matching pharmacy billing and 340B rules well can improve cash flow and cut costs. Teams in pharmacy, finance, and compliance should work together to avoid costly errors.
HRSA audits check if entities control who gets 340B drugs, how drugs are bought, and how they are given out. Auditors look at drug samples, policies, clinic eligibility, and Medicaid files to stop duplicate discounts.
Entities have 30 days to reply to audit results and 60 days to give a corrective action plan if problems are found. If plans are not done, entities may lose 340B program access. HRSA shares final audit results publicly, which can affect the entity’s reputation.
Drug makers also get audited to make sure they sell drugs at proper prices and enforce rules on discounts. This means covered entities must keep detailed records to pass reviews from both HRSA and manufacturers.
Technology helps manage data and get ready for audits in the 340B program. For those who run medical practices or IT, using automation and artificial intelligence (AI) can make work easier and reduce mistakes.
Automated Eligibility Verification
AI systems can check patient eligibility automatically during visits. They connect to Medicare and Medicaid data and reduce errors from manual checking. Some systems use national standards to improve verification.
Inventory and Transaction Tracking
Automated tools match drug buying with dispensing and billing. They keep audit trails and track drugs over many pharmacies. Reports can be made quickly for internal checks or audits.
Duplicate Discount Prevention
Compliance software watches for possible duplicate discount problems by checking payment and claims data. It warns about issues early so they can be fixed before audits.
Workflow Integration and Alerts
AI can analyze data to find unusual patterns and alert teams about possible problems. Alerts might show odd prescribing, missing patient eligibility, or strange inventory changes. Automated workflows also help track corrective actions and meet audit deadlines.
Reducing Administrative Burden
By automating tasks like data collection and reconciliation, staff can spend time on policy updates, training, and improving processes. This is useful for smaller practices or those with many contract pharmacies.
Covered entities with inpatient and outpatient services must carefully separate drugs used only for outpatients.
Managing many contract pharmacies means more detailed oversight, especially if there are more than five, which increases regulatory attention.
Federal and state Medicaid billing rules require working closely with state offices to avoid duplicate discounts. This often needs strong communication and data sharing.
Because HRSA audits and manufacturer reviews are increasing, regular internal audits, at least every three months, are advised to control risks.
Due to financial penalties and possible damage to reputation, providers should invest in technology and procedures that align pharmacy billing with 340B drug buying rules.
For healthcare providers in the U.S. using the 340B program, keeping clear and auditable records is very important. These records prove that discounted drugs reach the right patients.
The program is complex. Billing, multiple sites, and changing rules all create challenges. Technology and AI can help by automating patient eligibility checks, tracking inventory, and finding duplicate discounts. This lowers errors and helps get ready for audits.
Administrators, owners, and IT managers should build strong record-keeping systems and use technology that meets rules. This helps protect their organizations from money loss and supports the main goal of 340B: making medicines more affordable for those who need them.
The 340B Program allows healthcare facilities serving large numbers of uninsured and indigent patients to purchase outpatient drugs at reduced prices, enabling them to stretch federal resources and offer more comprehensive services. It mandates that participating drug manufacturers sell these drugs to enrolled entities at or below predetermined prices.
Common pitfalls include poor tracking of drug usage, incomplete or inaccurate records, ineligible drug usage, lack of contract pharmacy oversight, having too many contract pharmacies, poor record-keeping, using third-party administrators, failure to register ‘child’ sites, poor maintenance, and overlooked savings opportunities.
Tracking ensures compliance and helps hospitals prove that drugs purchased on a 340B account were administered in an eligible outpatient setting. Hospitals with mixed-use settings must implement safeguards to prevent diversion of drugs intended for outpatient use.
Incomplete or inaccurate records can lead to compliance failures. Hospitals may not correctly identify eligible patients or track 340B drug usage, potentially resulting in significant financial penalties and loss of program participation.
Nursing home patients are typically considered inpatients under 340B guidelines and, therefore, are not eligible for the program. Patients must have an established relationship with a covered entity and receive services from its employed or contracted healthcare professionals.
While contract pharmacies can increase access to 340B drugs, they introduce additional compliance challenges. Covered entities must oversee these pharmacies to ensure compliance, as they are ultimately responsible for any misuse.
Having more than five contract pharmacies can trigger regulatory scrutiny due to the difficulties in effective oversight. Limiting the number can help maintain compliance and simplify monitoring.
Maintaining auditable records is crucial for demonstrating compliance during inquiries from pharmaceutical manufacturers or regulatory agencies. It helps show that all 340B purchases were legitimate and appropriately managed.
No, hospitals cannot outsource their compliance responsibilities under the 340B Program. Although they may hire third-party administrators for program aspects, they must maintain full accountability for compliance.
Facilities should maximize 340B pricing eligibility across all purchases, including non-pharmacy purchases, and take into account drugs administered in offsite settings. Awareness of all potential savings can enhance the program’s benefits.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
